AcuCort AB (publ) (Spotlight Stock Market: ACUC) today announces a correction regarding the press release “AcuCort appoints Carl Johan Fredin as new CEO” that was published yesterday on March 16, 2020. The correction refers to the fact that the press release did not include the MAR label with reference to the EU Market Abuse Regulation.
The following information should have been included in the press release:
This information is information that AcuCort AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person below, on March 16, 2020.
For further information, please contact
Ebba Fåhraeus, Chairman of the Board, AcuCort AB
Phone: +46 (0)73 400 04 33
About AcuCort AB (publ)
AcuCort develops and commercializes ISICORT®, a new fast-dissolving oral film to put on the tongue, based on a well-known cortisone substance – dexamethasone. ISICORT® is a smart product in a new, innovative, patented and user-friendly dosage form primarily for the treatment of severe and acute allergic reactions, croup in children and chemotherapy-induced nausea and vomiting (CINV). The bioequivalence study that forms the basis of the application for marketing approval in Europe was carried out with positive results and a national hybrid application has been submitted to the Swedish Medical Products Agency. Taken together, this strengthens the company’s assessment that the time until commercialization of ISICORT® may be relatively short. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market in Sweden. Learn more at www.acucort.com